Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
30.06.25
/
50%
€7.60
Target price
30.06.26
€11.09
Performance (%)
-16.92%
Price
20.02.26
€6.32
Summary
This prediction is currently active. The price of Biocryst Pharmaceuticals has decreased since the start of the prediction. Compared to the start price this results in a performance of -16.92%. This prediction currently runs until 30.06.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | 10.691% | 10.691% |
| iShares Core DAX® | 1.432% | 2.628% |
| iShares Nasdaq 100 | 1.892% | -0.458% |
| iShares Nikkei 225® | -1.619% | 11.097% |
| iShares S&P 500 | 1.921% | 1.159% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank Of Canada. They now have a $13.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.59
30.01.26
30.01.26
€10.92
30.01.27
30.01.27
13.07%
20.02.26
20.02.26
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€8.90
06.05.25
06.05.25
€11.51
06.05.26
06.05.26
-29.02%
20.02.26
20.02.26
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.91
11.04.25
11.04.25
€9.75
11.04.26
11.04.26
6.87%
20.02.26
20.02.26
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.79
25.02.25
25.02.25
€10.47
25.02.26
25.02.26
-18.90%
20.02.26
20.02.26
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.61
05.11.24
05.11.24
€9.16
05.11.25
05.11.25
-6.99%
06.11.25
06.11.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.95
25.09.23
25.09.23
€9.44
25.09.24
25.09.24
-2.42%
26.09.24
26.09.24